Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.34 USD
−37.92 M USD
41.29 M USD
97.34 M
About MaxCyte, Inc.
Sector
Industry
CEO
Maher Masoud
Website
Headquarters
Rockville
Founded
1998
FIGI
BBG00R1W85V4
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MXCT is 3.55 USD — it has increased by 2.90% in the past 24 hours. Watch MaxCyte, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange MaxCyte, Inc. stocks are traded under the ticker MXCT.
MXCT stock has risen by 2.31% compared to the previous week, the month change is a −6.82% fall, over the last year MaxCyte, Inc. has showed a −18.39% decrease.
We've gathered analysts' opinions on MaxCyte, Inc. future price: according to them, MXCT price has a max estimate of 11.00 USD and a min estimate of 6.50 USD. Watch MXCT chart and read a more detailed MaxCyte, Inc. stock forecast: see what analysts think of MaxCyte, Inc. and suggest that you do with its stocks.
MXCT reached its all-time high on Jul 30, 2021 with the price of 17.44 USD, and its all-time low was 2.45 USD and was reached on Oct 5, 2023. View more price dynamics on MXCT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MXCT stock is 7.24% volatile and has beta coefficient of 0.95. Track MaxCyte, Inc. stock price on the chart and check out the list of the most volatile stocks — is MaxCyte, Inc. there?
Today MaxCyte, Inc. has the market capitalization of 374.46 M, it has increased by 0.88% over the last week.
Yes, you can track MaxCyte, Inc. financials in yearly and quarterly reports right on TradingView.
MaxCyte, Inc. is going to release the next earnings report on Apr 23, 2025. Keep track of upcoming events with our Earnings Calendar.
MXCT earnings for the last quarter are −0.11 USD per share, whereas the estimation was −0.12 USD resulting in a 8.33% surprise. The estimated earnings for the next quarter are −0.12 USD per share. See more details about MaxCyte, Inc. earnings.
MaxCyte, Inc. revenue for the last quarter amounts to 8.16 M USD, despite the estimated figure of 7.46 M USD. In the next quarter, revenue is expected to reach 7.76 M USD.
MXCT net income for the last quarter is −11.56 M USD, while the quarter before that showed −9.38 M USD of net income which accounts for −23.27% change. Track more MaxCyte, Inc. financial stats to get the full picture.
No, MXCT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 143.00 employees. See our rating of the largest employees — is MaxCyte, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MaxCyte, Inc. EBITDA is −41.95 M USD, and current EBITDA margin is −106.68%. See more stats in MaxCyte, Inc. financial statements.
Like other stocks, MXCT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MaxCyte, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MaxCyte, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MaxCyte, Inc. stock shows the strong sell signal. See more of MaxCyte, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.